METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE
To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; jpn |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | ANDREW GORDON WERNER DAVID BRADLEY WOODWARD LAI SAN THAM DAVID ANDREW COX ZVONKO MILICEVIC |
description | To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None
【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2024056908A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2024056908A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2024056908A3</originalsourceid><addsrcrecordid>eNrjZLDwdQ3x8HcJVvB3UwgN9vRzV3D0c1Fw9vcN8A_2DPH09wsGcvxCHD39QHIuoT6O7j6hIZ4urjwMrGmJOcWpvFCam0HJzTXE2UM3tSA_PrW4IDE5NS-1JN4rwMjAyMTA1MzSwMLRmChFAMbNKSI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><source>esp@cenet</source><creator>ANDREW GORDON WERNER ; DAVID BRADLEY WOODWARD ; LAI SAN THAM ; DAVID ANDREW COX ; ZVONKO MILICEVIC</creator><creatorcontrib>ANDREW GORDON WERNER ; DAVID BRADLEY WOODWARD ; LAI SAN THAM ; DAVID ANDREW COX ; ZVONKO MILICEVIC</creatorcontrib><description>To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None
【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし</description><language>eng ; jpn</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240423&DB=EPODOC&CC=JP&NR=2024056908A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240423&DB=EPODOC&CC=JP&NR=2024056908A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ANDREW GORDON WERNER</creatorcontrib><creatorcontrib>DAVID BRADLEY WOODWARD</creatorcontrib><creatorcontrib>LAI SAN THAM</creatorcontrib><creatorcontrib>DAVID ANDREW COX</creatorcontrib><creatorcontrib>ZVONKO MILICEVIC</creatorcontrib><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><description>To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None
【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLDwdQ3x8HcJVvB3UwgN9vRzV3D0c1Fw9vcN8A_2DPH09wsGcvxCHD39QHIuoT6O7j6hIZ4urjwMrGmJOcWpvFCam0HJzTXE2UM3tSA_PrW4IDE5NS-1JN4rwMjAyMTA1MzSwMLRmChFAMbNKSI</recordid><startdate>20240423</startdate><enddate>20240423</enddate><creator>ANDREW GORDON WERNER</creator><creator>DAVID BRADLEY WOODWARD</creator><creator>LAI SAN THAM</creator><creator>DAVID ANDREW COX</creator><creator>ZVONKO MILICEVIC</creator><scope>EVB</scope></search><sort><creationdate>20240423</creationdate><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><author>ANDREW GORDON WERNER ; DAVID BRADLEY WOODWARD ; LAI SAN THAM ; DAVID ANDREW COX ; ZVONKO MILICEVIC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2024056908A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>ANDREW GORDON WERNER</creatorcontrib><creatorcontrib>DAVID BRADLEY WOODWARD</creatorcontrib><creatorcontrib>LAI SAN THAM</creatorcontrib><creatorcontrib>DAVID ANDREW COX</creatorcontrib><creatorcontrib>ZVONKO MILICEVIC</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ANDREW GORDON WERNER</au><au>DAVID BRADLEY WOODWARD</au><au>LAI SAN THAM</au><au>DAVID ANDREW COX</au><au>ZVONKO MILICEVIC</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><date>2024-04-23</date><risdate>2024</risdate><abstract>To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None
【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; jpn |
recordid | cdi_epo_espacenet_JP2024056908A |
source | esp@cenet |
subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
title | METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T18%3A57%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ANDREW%20GORDON%20WERNER&rft.date=2024-04-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2024056908A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |